Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term Registry
Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Gerasimos Filippatos(National and Kapodistrian University of Athens), Frank Ruschitzka(Kantonsspital St. Gallen), María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Giuseppe Ambrosio(University of Perugia), Andrew J.S. Coats(The Heart Research Institute), Mitja Lainščak, Lars H. Lund(Karolinska University Hospital), Petar Seferović, Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), John Parissis(National and Kapodistrian University of Athens), Massimo Piepoli(University of Milan), Aldo P. Maggioni(Health Care Foundation), Roberto Ferrari(University of Ferrara), Cécile Laroche(European Society of Cardiology), Stefan D. Anker(Bayer (Germany)), Veli‐Pekka Harjola(Polskie Towarzystwo Gastroenterologii), Cândida Fonseca
Cited by 904
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k